You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameImmune Globulin Human
Accession NumberDB00028  (BTD00091, BIOD00091)
TypeBiotech
GroupsApproved, Investigational
Description

Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.

Protein structureDb00028
Related Articles
Protein chemical formulaC6332H9826N1692O1980S42
Protein average weight142682.3 Da
Sequences
>IGG1
PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
>IgA2
ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
HVNVSVVMAEVDGTCY
Download FASTA Format
Synonyms
Human IGG
Human Immunoglobulin G
Human Normal Immunoglobulin
Immune globulin (human)
Immune Globulin Intravenous
Immune Globulin Subcutaneous
Immunoglobulin G (human)
Immunoglobulin G, Human
Intravenous Immunoglobulin
IVIg
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bivigaminjection, solution1 g/10mLintravenousKedrion Biopharma, Inc.2013-02-04Not applicableUs
Bivigaminjection, solution10 g/100mLintravenousBiotest Pharmaceuticals Corporation2013-02-04Not applicableUs
Bivigaminjection, solution5 g/50mLintravenousBiotest Pharmaceuticals Corporation2013-02-04Not applicableUs
Carimune Nanofilteredinjection, powder, lyophilized, for solution12 g/1intravenousCsl Behring Ag2009-02-10Not applicableUs
Carimune Nanofilteredinjection, powder, lyophilized, for solution6 g/1intravenousCsl Behring Ag2009-02-10Not applicableUs
Carimune Nanofilteredinjection, powder, lyophilized, for solution3 g/1intravenousCsl Behring Ag2009-02-10Not applicableUs
Flebogamma Difinjection, solution5 g/50mLintravenousGRIFOLS USA, LLC2010-07-27Not applicableUs
Flebogamma Difinjection, solution.05 g/mLintravenousGRIFOLS USA, LLC2006-12-21Not applicableUs
Gamastanliquid16.5 %intramuscularCutter Med & Biol, Division Of Miles Canada Ltd.1951-12-311998-09-25Canada
Gamastan S/dsolution18 %intramuscularGrifols Therapeutics Inc2004-03-04Not applicableCanada
Gamastan S/dinjection.165 g/mLintramuscularGRIFOLS USA, LLC1996-08-14Not applicableUs
Gamimune N 10% (iv)solution100 mgintravenousTalecris Biotherapeutics Inc2000-05-162006-08-03Canada
Gamimune N 5% (iv)solution50 mgintravenousTalecris Biotherapeutics Inc1997-01-172006-08-03Canada
Gamimune N Inj 5% (iv)liquid50 mgintravenousCutter Med & Biol, Division Of Miles Canada Ltd.1986-12-311998-09-25Canada
Gammagardinjection, solution100 mg/mLintravenous; subcutaneousBaxter Healthcare Corporation2005-04-27Not applicableUs
Gammagard Liquidsolution10 %intravenousBaxalta Canada Corporation2007-08-08Not applicableCanada
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dkitBaxter Healthcare Corporation2011-01-03Not applicableUs
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dpowder for solution10 gintravenousBaxalta Canada Corporation1997-08-22Not applicableCanada
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dpowder for solution5 gintravenousBaxalta Canada Corporation1997-08-22Not applicableCanada
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dkitBaxter Healthcare Corporation1994-05-10Not applicableUs
Gammagard S/dpowder for solution2.5 gintravenousBaxalta Canada Corporation1997-08-222015-05-12Canada
Gammagard S/d (iv)powder for solution0.5 gintravenousBaxter Corporation1997-08-222013-11-04Canada
Gammakedinjection10 g/100mLintravenousKedrion Biopharma, Inc2010-10-13Not applicableUs
Gammaplexsolution5 g/100mLintravenousBio Products Laboratory Limited2010-11-01Not applicableUs
Gammar Inj 165mg/mlliquid165 mgintramuscularArmour Pharmaceutical Co.1991-12-311999-12-15Canada
Gamunexsolution10 gintravenous; subcutaneousGrifols Therapeutics Inc2003-10-22Not applicableCanada
Gamunex-Cinjection10 g/100mLintravenousGRIFOLS USA, LLC2010-10-13Not applicableUs
Hizentrasolution200 mgsubcutaneousCsl Behring Canada Inc2011-10-13Not applicableCanada
Hizentraliquid.2 g/mLsubcutaneousCsl Behring Ag2011-10-03Not applicableUs
Hizentraliquid.2 g/mLsubcutaneousCsl Behring Ag2011-10-03Not applicableUs
Hizentraliquid.2 g/mLsubcutaneousCsl Behring Ag2011-10-03Not applicableUs
Hizentraliquid.2 g/mLsubcutaneousCsl Behring Ag2011-10-03Not applicableUs
Hyperrho S/d Full Dosesolution1500 unitintramuscularGrifols Therapeutics IncNot applicableNot applicableCanada
Hyperrho S/d Full Dosesolution1500 unitintramuscularGrifols Therapeutics IncNot applicableNot applicableCanada
Igivnexsolution10 gintravenous; subcutaneousGrifols Therapeutics Inc2006-05-24Not applicableCanada
Immune Globulin Intravenous (human) 5%liquid50 mgintravenousBayer Corporation1996-12-311998-09-28Canada
Immune Globulin Intravenous (human), 10%solution10 gintravenousTalecris Biotherapeutics Inc2000-07-312006-08-03Canada
Immune Globulin Intravenous (human), 5%solution5 gintravenousTalecris Biotherapeutics Inc1997-11-032006-08-03Canada
Immune Serum Globulin (human)solution18 %intramuscularGrifols Therapeutics Inc1997-04-21Not applicableCanada
Octagam 10%solution100 mgintravenousOctapharma Pharmazeutika Produktionsges M B H2013-04-04Not applicableCanada
Octagam 5%solution50 mgintravenousOctapharma Pharmazeutika Produktionsges M B HNot applicableNot applicableCanada
Octagam Immune Globulin (human)solution50 mg/mLintravenousOctapharma Usa Inc2004-05-21Not applicableUs
Octagam Immune Globulin (human)solution50 mg/mLintravenousOctapharma Ab2006-04-14Not applicableUs
Octagam Immune Globulin (human)solution50 mg/mLintravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2004-05-21Not applicableUs
Octagam Immune Globulin (human)solution100 mg/mLintravenousOctapharma Usa Inc2004-05-21Not applicableUs
Privigenliquid40 g/200mLintravenousCsl Behring Ag2009-01-20Not applicableUs
Privigensolution10 %intravenousCsl Behring Canada Inc2009-01-08Not applicableCanada
Privigenliquid20 g/200mLintravenousCsl Behring Ag2009-01-20Not applicableUs
Privigenliquid10 g/100mLintravenousCsl Behring Ag2009-01-20Not applicableUs
Privigenliquid5 g/50mLintravenousCsl Behring Ag2009-01-20Not applicableUs
Sandoglobulin Nf Liquidsolution120 gintravenousCsl Behring Canada Inc2007-06-282010-04-20Canada
Vivaglobinsolution160 mg/mLsubcutaneousCSL Behring LLC2006-01-09Not applicableUs
Vivaglobinsolution160 mgsubcutaneousCsl Behring Canada Inc2007-03-012015-04-02Canada
Winrholiquid1500 [iU]/mLintramuscular; intravenousCangene Bio Pharma Inc.2005-03-31Not applicableUs
Winrholiquid2500 [iU]/mLintramuscular; intravenousCangene Bio Pharma Inc.2005-03-31Not applicableUs
Winrholiquid600 [iU]/mLintramuscular; intravenousCangene Bio Pharma Inc.2005-03-31Not applicableUs
Winrholiquid5000 [iU]/mLintramuscular; intravenousCangene Bio Pharma Inc.2004-03-31Not applicableUs
Winrholiquid15000 [iU]/mLintramuscular; intravenousCangene Bio Pharma Inc.2005-03-31Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CivacirNot Available
FlebogammaInstituto Grifols SA
Brand mixtures
NameLabellerIngredients
HyqviaBaxalta Us Inc.
Iveegam Immuno 5000mg (iv)Baxter Ag
SaltsNot Available
Categories
UNII66Y330CJHS
CAS number9007-83-4
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.
PharmacodynamicsUsed as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.
Mechanism of actionIVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life>20 hours (mammalian reticulocytes, in vitro).
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Bacteria and protozoa
  • Various viruses
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous1 g/10mL
Injection, solutionintravenous10 g/100mL
Injection, solutionintravenous5 g/50mL
Injection, powder, lyophilized, for solutionintravenous12 g/1
Injection, powder, lyophilized, for solutionintravenous3 g/1
Injection, powder, lyophilized, for solutionintravenous6 g/1
Injection, solutionintravenous.05 g/mL
Liquidintramuscular16.5 %
Injectionintramuscular.165 g/mL
Solutionintramuscular18 %
Solutionintravenous50 mg
Injection, solutionintravenous; subcutaneous100 mg/mL
Solutionintravenous10 %
Kit
Powder for solutionintravenous10 g
Powder for solutionintravenous2.5 g
Powder for solutionintravenous5 g
Powder for solutionintravenous0.5 g
Solutionintravenous5 g/100mL
Liquidintramuscular165 mg
Solutionintravenous; subcutaneous10 g
Injectionintravenous10 g/100mL
Liquidsubcutaneous.2 g/mL
Solutionsubcutaneous200 mg
Solutionintramuscular1500 unit
Kit
Liquidintravenous50 mg
Solutionintravenous10 g
Solutionintravenous5 g
Kit; liquid; powder for solutionintravenous
Solutionintravenous100 mg
Solutionintravenous100 mg/mL
Solutionintravenous50 mg/mL
Liquidintravenous10 g/100mL
Liquidintravenous20 g/200mL
Liquidintravenous40 g/200mL
Liquidintravenous5 g/50mL
Solutionintravenous120 g
Solutionsubcutaneous160 mg
Solutionsubcutaneous160 mg/mL
Liquidintramuscular; intravenous1500 [iU]/mL
Liquidintramuscular; intravenous15000 [iU]/mL
Liquidintramuscular; intravenous2500 [iU]/mL
Liquidintramuscular; intravenous5000 [iU]/mL
Liquidintramuscular; intravenous600 [iU]/mL
Prices
Unit descriptionCostUnit
Hypertet s-d 250 unit syringe324.23USD syringe
Hyperrab s-d vial224.07USD ml
Nabi-hb vial176.34USD ml
Hyperhep b s-d vial165.04USD ml
Hizentra 1 gram/5 ml vial30.24USD ml
Hizentra 2 gram/10 ml vial30.24USD ml
Hizentra 4 gram/20 ml vial30.24USD ml
Gamastan s-d vial24.44USD ml
Gammagard liquid 10% vial13.79USD ml
Gamunex 10% vial11.6USD ml
Immune globulin vial9.34USD ml
Flebogamma 5% vial4.84USD ml
Flebogamma dif 5% vial4.84USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
hydrophobicity-0.331Not Available
isoelectric point8.13Not Available
References
Synthesis Reference

Wolfgang Stephan, “Production of intravenously applicable native human immune globulin having a normal half-life.” U.S. Patent US4082734, issued July, 1970.

US4082734
General References
  1. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9. [PubMed:20970960 ]
  2. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  3. Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. [PubMed:16998749 ]
  4. Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. [PubMed:12032582 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 80:04.00
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
EstradiolEstradiol may increase the thrombogenic activities of Intravenous Immunoglobulin.
Estrone sulfateEstropipate may increase the thrombogenic activities of Intravenous Immunoglobulin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.
Gene Name:
FCGR1A
Uniprot ID:
P12314
Molecular Weight:
42631.525 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Immunoglobulin receptor activity
Specific Function:
May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.
Gene Name:
FCGR1B
Uniprot ID:
Q92637
Molecular Weight:
32231.795 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Not Available
Specific Function:
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.
Gene Name:
FCGR2A
Uniprot ID:
P12318
Molecular Weight:
35000.42 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Not Available
Specific Function:
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells ...
Gene Name:
FCGR2B
Uniprot ID:
P31994
Molecular Weight:
34043.355 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transmembrane signaling receptor activity
Specific Function:
Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.
Gene Name:
FCGR2C
Uniprot ID:
P31995
Molecular Weight:
35577.96 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Not Available
Specific Function:
Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.
Gene Name:
FCGR3A
Uniprot ID:
P08637
Molecular Weight:
29088.895 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Not Available
Specific Function:
Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
Gene Name:
FCGR3B
Uniprot ID:
O75015
Molecular Weight:
26215.64 Da
References
  1. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
  2. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  3. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Receptor binding
Specific Function:
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local i...
Gene Name:
C3
Uniprot ID:
P01024
Molecular Weight:
187146.73 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Endopeptidase inhibitor activity
Specific Function:
Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antige...
Gene Name:
C4A
Uniprot ID:
P0C0L4
Molecular Weight:
192783.805 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Endopeptidase inhibitor activity
Specific Function:
Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein an...
Gene Name:
C4B
Uniprot ID:
P0C0L5
Molecular Weight:
192749.785 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Receptor binding
Specific Function:
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to th...
Gene Name:
C5
Uniprot ID:
P01031
Molecular Weight:
188303.705 Da
References
  1. Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9. [PubMed:20441428 ]
  2. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. [PubMed:17351760 ]
  3. Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. [PubMed:17911465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 25, 2016 11:15